Listed below are scientific articles related to polycythemia vera, essential thrombocythemia, and myelofibrosis. For your convenience, we have provided links to these abstracts and articles. If a link is no longer available or if you are unable to download an article, please contact the publisher directly to obtain this information.
| MF |
| Anand K, Burns EA, Ensor J, Rice L, Pingali SR. Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review. Clin Lymphoma Myeloma Leuk. 2019 Aug 26. pii: S2152-2650(19)31325-4. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31325-4/fulltext |
| Barbui T, Thiele J, Gisslinger H, et al. Comments on pre-fibrotic myelofibrosis and how should it be managed. Br J Haematol. 2019;186:358-360. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15840 |
| Barbui T, De Stefano V, Falanga A, et al. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer J. 2019;9:61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687826/ |
| Blair HA. Fedratinib: First Approval. Drugs. 2019 Oct;79:1719-1725. doi: 10.1007/s40265-019-01205-x. https://link.springer.com/article/10.1007%2Fs40265-019-01205-x |
| Bose P, Alfayez M, Verstovsek S. New concepts of treatment for patients with myelofibrosis. Curr Treat Options Oncol. 2019;20:5. doi: 10.1007/s11864-019-0604-y. https://link.springer.com/article/10.1007%2Fs11864-019-0604-y |
| Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2019 Oct 19. doi: 10.1007/s12185-019-02758-z. [Epub ahead of print]. https://link.springer.com/article/10.1007%2Fs12185-019-02758-z |
| Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019;60:1176-1185. doi: 10.11406/rinketsu.60.1176. https://www.jstage.jst.go.jp/article/rinketsu/60/9/60_1176/_article |
| Cottin L, Riou J, Orvain C, et al. Sequential mutational evaluation of CALR‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol. 2019; 2019 Nov 11. doi: 10.1111/bjh.16276. [Epub ahead of print]. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16276 |
| Cruz NM, Gergis U, Silver RT. Myelofibrosis: best practices, controversies and 2019 update. Expert Rev Hematol. 2019 Nov 30:1-14. doi: 10.1080/17474086.2020.1691519. [Epub ahead of print]. https://www.tandfonline.com/doi/abs/10.1080/17474086.2020.1691519?journalCode=ierr20 |
| Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104:e551-e554. http://www.haematologica.org/content/104/12/e551.long |
| Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors. Curr Hematol Malig Rep. 2019;14:460-468. doi: 10.1007/s11899-019-00538-4. https://link.springer.com/article/10.1007%2Fs11899-019-00538-4 |
| Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133:790-794. doi: 10.1182/blood-2018-11-876888. Epub 2019 Jan 2. https://ashpublications.org/blood/article-abstract/133/8/790/260592/Luspatercept-for-the-treatment-of-anemia-in?redirectedFrom=fulltext |
| Gangat N, Marinaccio C, Swords R, et al. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. Clin Cancer Res. 2019;25:4898-4906. https://clincancerres.aacrjournals.org/content/25/16/4898.long |
| Gerds AT. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program. 2019;2019:407-414. https://ashpublications.org/hematology/article-abstract/2019/1/407/422579/Beyond-JAK-STAT-novel-therapeutic-targets-in-Ph?redirectedFrom=fulltext |
| Kuykendall AT, Talati C, Padron E. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10. https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25625 |
| Maekawa T, Kato S, Kawamura T, et al. Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood. 2019;134:814-825. doi: 10.1182/blood.2019000051. Epub 2019 Jul 3. https://ashpublications.org/blood/article-abstract/134/10/814/260635/Increased-SLAMF7high-monocytes-in-myelofibrosis?redirectedFrom=fulltext |
| Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019;17:405-411. https://www.ncbi.nlm.nih.gov/pubmed/31449507 |
| Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol. 2019;17:299-307. https://www.ncbi.nlm.nih.gov/pubmed/31188809 |
| Masarova L, Bose P, Verstovsek S. The rationale for immunotherapy in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2019;14:310-327. https://link.springer.com/article/10.1007%2Fs11899-019-00527-7 |
| Mascarenhas J, Marcellino BK, Lu M, et al. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). Leuk Res. 2019;88:106272. doi: 10.1016/j.leukres.2019.106272. [Epub ahead of print]. https://www.sciencedirect.com/science/article/pii/S0145212619307179?via%3Dihub |
| Mascarenhas J, Baer MR, Kessler C, et al. Phase II trial of lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2019;60:1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. https://www.tandfonline.com/doi/abs/10.1080/10428194.2018.1532509?journalCode=ilal20 |
| Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784750/ |
| DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN6, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659-668. doi: 10.3324/haematol.2018.206151. Epub 2019 Mar 14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442950/ |
| McLornan D, Szydlo R, Koster L, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5. https://www.bbmt.org/article/S1083-8791(19)30418-5/fulltext |
| Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19:590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580484/ |
| Mesa RA, Su Y, Woolfson A, et al. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Qual Life Outcomes. 2019;17:61. doi: 10.1186/s12955-019-1121-1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460742/ |
| Mesa RA. Proactive steps to optimize the management of polycythemia vera and myelofibrosis. Clin Adv Hematol Oncol. 2019;17:475-477. |
| Mina AA, Stein B. Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients? Curr Hematol Malig Rep. 2019;14:137-144. https://link.springer.com/article/10.1007%2Fs11899-019-00514-y |
| Mora B, Rumi E, Guglielmelli P, et al. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019;8:4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675726/ |
| Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol. 2019;84:891-898. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768916/ |
| Palmer J, Kosiorek HE, Wolschke C, et al. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant. 2019;25:2267-2273. doi: 10.1016/j.bbmt.2019.07.001. Epub 2019 Jul 6. https://www.bbmt.org/article/S1083-8791(19)30433-1/fulltext |
| Sapre M, Tremblay D, Wilck E, et al. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. Sci Rep. 2019; 9: 16609. Published online 2019 Nov 12. doi: 10.1038/s41598-019-53056-x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851362/ |
| Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O’Mahony A. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS One. 2019;14:e0222944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764664/ |
| Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019:397-406. https://ashpublications.org/hematology/article-abstract/2019/1/397/422631/From-Budd-Chiari-syndrome-to-acquired-von?redirectedFrom=fulltext |
| Strati P, Abdelrahim M, Selamet U, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611-1616. https://link.springer.com/article/10.1007%2Fs00277-019-03708-9 |
| Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30653-0/fulltext |
| Tremblay D, King A, Li L, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2019 Nov 12:1-8. doi: 10.1080/10428194.2019.1688323. [Epub ahead of print]. https://www.tandfonline.com/doi/abs/10.1080/10428194.2019.1688323?journalCode=ilal20 |
| Tremblay D, Putra J, Vogel A, et al. The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Rep Hematol. 2019;2019:3294046. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339753/ |
| Vallapureddy RR, Mudireddy M, Penna D, et al. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019;9:12. doi: 10.1038/s41408-019-0175-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347609/ |
| Winton EF. Myelofibrosis management after ruxolitinib failure. Clin Lymph Myeloma Leuk. 2019;19(supplement 19):S12-S14. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31174-7/fulltext |
| Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living With MPN patient survey. Ann Hematol. 2019;98:1119-1125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469835/
|
| PV |
| Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719465/ |
| Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019 Oct 18;10:359-371. doi: 10.2147/JBM.S189922. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805785/ |
| Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104:e551-e554. http://www.haematologica.org/content/104/12/e551.long |
| Foltz L, Pica GM, Zerazhi H, et al. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leuk Lymphoma. 2019 Jul 30:1-10. doi: 10.1080/10428194.2019.1636985. [Epub ahead of print] https://www.tandfonline.com/doi/abs/10.1080/10428194.2019.1636985?journalCode=ilal20 |
| Gangat N, Marinaccio C, Swords R, et al. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. Clin Cancer Res. 2019;25:4898-4906. https://clincancerres.aacrjournals.org/content/25/16/4898.long |
| Gerds AT. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program. 2019;2019:407-414. https://ashpublications.org/hematology/article-abstract/2019/1/407/422579/Beyond-JAK-STAT-novel-therapeutic-targets-in-Ph?redirectedFrom=fulltext |
| Grunwald MR, Burke JM, Kuter DJ, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19:579-584.e1. doi: 10.1016/j.clml.2019.06.001. Epub 2019 Jun 13. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)30312-X/fulltext |
| Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071-1082. doi: 10.1007/s00277-019-03625-x. Epub 2019 Mar 8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469649/ |
| Ianotto JC, Curto-Garcia , Lauermanova M1, Radia D, Kiladjian JJ, Harrison CN. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019;104:1580-1588. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669170/ |
| Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019;17:405-411. https://www.ncbi.nlm.nih.gov/pubmed/31449507 |
| Masarova L, Bose P, Verstovsek S. The Rationale for immunotherapy in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2019;14:310-327. https://link.springer.com/article/10.1007%2Fs11899-019-00527-7 |
| Mascarenhas J, Kosiorek H, Prchal J, et al. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019;33:2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. https://www.nature.com/articles/s41375-019-0524-7 |
| Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784750/ |
| Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19:590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580484/ |
| Mesa RA. Proactive steps to optimize the management of polycythemia vera and myelofibrosis. Clin Adv Hematol Oncol. 2019;17:475-477. |
| Mina AA, Stein B. Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients? Curr Hematol Malig Rep. 2019;14:137-144. https://link.springer.com/article/10.1007%2Fs11899-019-00514-y |
| Parasuraman S, Yu J, Paranagama D, et al. Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data. Ann Hematol. 2019;98:2533-2539. doi: 10.1007/s00277-019-03793-w. Epub 2019 Sep 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848033/ |
| Ritchie EK. Drug development challenges in polycythemia vera. Blood. 2019;134:495-496. doi: 10.1182/blood.2019001875. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019001875 |
| Sankar K, Stein BL, Rampal RK. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Treat Res. 2019;179:159-178. https://link.springer.com/chapter/10.1007%2F978-3-030-20315-3_11 |
| Shaw G, Berg R. Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera. Clin Med Res. 2019 Oct 3. pii: cmr.2019.1483. doi: 10.3121/cmr.2019.1483. [Epub ahead of print] http://www.clinmedres.org/content/early/2019/09/30/cmr.2019.1483.long |
| Spivak JL. How I treat polycythemia vera. Blood. 2019;134:341-352. doi: 10.1182/blood.2018834044. Epub 2019 May 31. https://ashpublications.org/blood/article-abstract/134/4/341/260695/How-I-treat-polycythemia-vera?redirectedFrom=fulltext |
| Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019:397-406. https://ashpublications.org/hematology/article-abstract/2019/1/397/422631/From-Budd-Chiari-syndrome-to-acquired-von?redirectedFrom=fulltext |
| Strati P, Abdelrahim M, Selamet U, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611-1616. https://link.springer.com/article/10.1007%2Fs00277-019-03708-9 |
| Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94:599-610. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30653-0/fulltext |
| Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133-143. https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25303 |
| Tremblay D, Putra J, Vogel A, et al. The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Rep Hematol. 2019;2019:3294046. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339753/ |
| Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498-1509. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000428 |
| Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Ann Hematol. 2019;98:1119-1125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469835/
|
| ET |
| Baerlocher GM, Haubitz M, Braschler TR, et al. Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia. Blood Adv. 2019;3:3724-3728. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880912/ |
| Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719465/ |
| Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica. 2019;104:e551-e554. http://www.haematologica.org/content/104/12/e551.long |
| Gangat N, Marinaccio C, Swords R, et al. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019;25:4898-4906. https://clincancerres.aacrjournals.org/content/25/16/4898.long |
| Gerds AT. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program. 2019;2019:407-414. https://ashpublications.org/hematology/article-abstract/2019/1/407/422579/Beyond-JAK-STAT-novel-therapeutic-targets-in-Ph?redirectedFrom=fulltext |
| Geringer J, Fenderson J, Osswald M. Essential Thrombocythemia Complicated by Occlusive Thrombosis of the Abdominal Aorta. Case Rep Hematol. 2019 Mar 26;2019:9454501. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458875/ |
| Gisslinger H, Buxhofer-Ausch V, Hodisch J, et al. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial. Br J Haematol. 2019;185:691-700. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594023/ |
| Ianotto JC, Curto-Garcia , Lauermanova M1, Radia D, Kiladjian JJ, Harrison CN. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019;104:1580-1588. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669170/ |
| Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019;17:405-411. https://www.ncbi.nlm.nih.gov/pubmed/31449507 |
| Masarova L, Verstovsek S. Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs. 2019;24:93-105. Epub 2019 May 14. https://www.tandfonline.com/doi/abs/10.1080/14728214.2019.1615437?journalCode=iemd20 |
| Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784750/ |
| Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019;19:590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580484/ |
| Mina AA, Stein B. Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients? Curr Hematol Malig Rep. 2019;14:137-144. https://link.springer.com/article/10.1007%2Fs11899-019-00514-y |
| Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Rev Hematol. 2019;12:159-171. https://www.tandfonline.com/doi/abs/10.1080/17474086.2019.1585239?journalCode=ierr20 |
| Sankar K, Stein BL, Rampal RK. Thrombosis in the Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Treat Res. 2019;179:159-178. https://link.springer.com/chapter/10.1007%2F978-3-030-20315-3_11 |
| Santoro M, Accurso V, Mancuso S, et al. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. Hematol Oncol. 2019;37:434-437. https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2670 |
| Silver RT, Krichevsky S. Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values. Haematologica. 2019;104:2200-2205. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821600/ |
| Strati P, Abdelrahim M, Selamet U, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611-1616. https://link.springer.com/article/10.1007%2Fs00277-019-03708-9 |
| Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019:397-406. https://ashpublications.org/hematology/article-abstract/2019/1/397/422631/From-Budd-Chiari-syndrome-to-acquired-von?redirectedFrom=fulltext |
| Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic Patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30653-0/fulltext |
| Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381:2135-2144. https://www.nejm.org/doi/full/10.1056/NEJMcp1816082?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed |
| Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133-143. https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25303 |
| Tefferi A, Szuber N, Vallapureddy RR, et al. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019;94:5-9. https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25294 |
| Tremblay D, Putra J, Vogel A, et al. The Implications of liver biopsy results in patients with myeloproliferative neoplasms being treated with ruxolitinib. Case Rep Hematol. 2019;2019:3294046. eCollection 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339753/ |
| Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498-1509. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000428 |
| Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Ann Hematol. 2019;98:1119-1125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469835/
|
